Tom 14, Nr 2 (2017)
Artykuł przeglądowy
Opublikowany online: 2017-06-30
Wyświetlenia strony
1135
Wyświetlenia/pobrania artykułu
78615
Unikatowy wpływ arypiprazolu na funkcje poznawcze — miejsce w leczeniu młodzieży i pacjentów w wieku podeszłym
Psychiatria 2017;14(2):78-84.
Streszczenie
Arypiprazol jest lekiem przeciwpsychotycznym wykazującym unikatowe właściwości farmakologiczne — ago-antagonistyczne w stosunku do recpetora D2. Jest klasyfikowany jako lek III generacji. Wyniki badań klinicznych i przedklinicznych wskazują na wysoką skuteczność i bezpieczeństwo arypiprazolu w leczeniu populacji pacjentów poniżej 18. roku życia oraz chorych w podeszłym wieku. Wynika to zarówno z jego wysokiego profilu bezpieczeństwa, jak i braku negatywnego wpływu na funkcje poznawcze. Cechy te odróżniają arypiprazol od innych leków przeciwpsychotycznych. Celem artykułu jest przedstawienie unikatowych właściwości arypiprazolu, przegląd badań klinicznych i dyskusja propozycji zastosowania arypiprazolu w wymienionych grupach wiekowych. Poza korzystnym wpływem na funkcje poznawcze należy także podkreślić jego pozytywny wpływ na stężenie prolaktyny i możliwość zostosowania u pacjentów z hiperprolaktynemią polekową.
Słowa kluczowe: arypiprazolfunkcje poznawczemłodzieżpacjenci w wieku podeszłym
Referencje
- Mailman RB, Murthy V. Third generation antipsychotic drugs: partial agonism or receptor functional selectivity? Curr Pharm Des. 2010; 16(5): 488–501.
- Kirino E. Profile of aripiprazole in the treatment of bipolar disorder in children and adolescents. Adolesc Health Med Ther. 2014; 5: 211–221.
- Nagai T, Murai R, Matsui K, et al. Aripiprazole ameliorates phencyclidine-induced impairment of recognition memory through dopamine D1 and serotonin 5-HT1A receptors. Psychopharmacology (Berl). 2009; 202(1-3): 315–328.
- Lieberman JA. Dopamine partial agonists: a new class of antipsychotic. CNS Drugs. 2004; 18(4): 251–267.
- Shapiro DA, Renock S, Arrington E, et al. Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology. Neuropsychopharmacology. 2003; 28(8): 1400–1411.
- Urban JD, Vargas GA, von Zastrow M, et al. Aripiprazole has functionally selective actions at dopamine D2 receptor-mediated signaling pathways. Neuropsychopharmacology. 2007; 32(1): 67–77.
- Kikuchi T, Tottori K, Uwahodo Y, et al. 7-(4-[4-(2,3-Dichlorophenyl)-1-piperazinyl]butyloxy)-3,4-dihydro-2(1H)-quinolinone (OPC-14597), a new putative antipsychotic drug with both presynaptic dopamine autoreceptor agonistic activity and postsynaptic D2 receptor antagonistic activity. J Pharmacol Exp Ther. 1995; 274(1): 329–336.
- Friedman JH, Berman RM, Goetz CG, et al. Open-label flexible-dose pilot study to evaluate the safety and tolerability of aripiprazole in patients with psychosis associated with Parkinson's disease. Mov Disord. 2006; 21(12): 2078–2081.
- Schreiber R, Newman-Tancredi A. Improving cognition in schizophrenia with antipsychotics that elicit neurogenesis through 5-HT(1A) receptor activation. Neurobiol Learn Mem. 2014; 110: 72–80.
- Bervoets C, Morrens M, Vansteelandt K, et al. Effect of aripiprazole on verbal memory and fluency in schizophrenic patients : results from the ESCAPE study. CNS Drugs. 2012; 26(11): 975–982.
- Matsuda Y, Sato S, Iwata K, et al. Effects of risperidone and aripiprazole on neurocognitive rehabilitation for schizophrenia. Psychiatry Clin Neurosci. 2014; 68(6): 425–431.
- Maat A, Cahn W, Gijsman HJ, et al. Open, randomized trial of the effects of aripiprazole versus risperidone on social cognition in schizophrenia. Eur Neuropsychopharmacol. 2014; 24(4): 575–584.
- Sakurai H, Bies RR, Stroup ST, et al. Dopamine D2 receptor occupancy and cognition in schizophrenia: analysis of the CATIE data. Schizophr Bull. 2013; 39(3): 564–574.
- Uchida H, Rajji TK, Mulsant BH, et al. D2 receptor blockade by risperidone correlates with attention deficits in late-life schizophrenia. J Clin Psychopharmacol. 2009; 29(6): 571–575.
- Mishara AL, Goldberg TE. A meta-analysis and critical review of the effects of conventional neuroleptic treatment on cognition in schizophrenia: opening a closed book. Biol Psychiatry. 2004; 55(10): 1013–1022.
- Woodward ND, Purdon SE, Meltzer HY, et al. A meta-analysis of cognitive change with haloperidol in clinical trials of atypical antipsychotics: dose effects and comparison to practice effects. Schizophr Res. 2007; 89(1-3): 211–224.
- Kołaczkowski M, Mierzejewski P, Bienkowski P, et al. Antipsychotic, antidepressant, and cognitive-impairment properties of antipsychotics: rat profile and implications for behavioral and psychological symptoms of dementia. Naunyn Schmiedebergs Arch Pharmacol. 2014; 387(6): 545–557.
- Lewinsohn PM, Hops H, Roberts RE, et al. Adolescent psychopathology: I. Prevalence and incidence of depression and other DSM-III-R disorders in high school students. J Abnorm Psychol. 1993; 102(1): 133–144.
- Van Meter AR, Moreira AL, Youngstrom EA. Meta-analysis of epidemiologic studies of pediatric bipolar disorder. J Clin Psychiatry. 2011; 72(9): 1250–1256.
- Rasimas JJ, Liebelt EL. Adverse Effects and Toxicity of the Atypical Antipsychotics: What is Important for the Pediatric Emergency Medicine Practitioner. Clin Pediatr Emerg Med. 2012; 13(4): 300–310.
- Doey T. Aripiprazole in pediatric psychosis and bipolar disorder: a clinical review. J Affect Disord. 2012; 138 Suppl: S15–S21.
- Findling RL, Robb A, Nyilas M, et al. A multiple-center, randomized, double-blind, placebo-controlled study of oral aripiprazole for treatment of adolescents with schizophrenia. Am J Psychiatry. 2008; 165(11): 1432–1441.
- Findling RL, Correll CU, Nyilas M, et al. Acute treatment of pediatric bipolar I disorder, manic or mixed episode, with aripiprazole: a randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 2009; 70(10): 1441–1451.
- Findling RL, Correll CU, Nyilas M, et al. Aripiprazole for the treatment of pediatric bipolar I disorder: a 30-week, randomized, placebo-controlled study. Bipolar Disord. 2013; 15(2): 138–149.
- Fraguas D, Correll CU, Merchán-Naranjo J, et al. Efficacy and safety of second-generation antipsychotics in children and adolescents with psychotic and bipolar spectrum disorders: comprehensive review of prospective head-to-head and placebo-controlled comparisons. Eur Neuropsychopharmacol. 2011; 21(8): 621–645.
- McKeage K. Aripiprazole: a review of its use in the treatment of manic episodes in adolescents with bipolar I disorder. CNS Drugs. 2014; 28(2): 171–183.
- Zuddas A, Zanni R, Usala T. Second generation antipsychotics (SGAs) for non-psychotic disorders in children and adolescents: a review of the randomized controlled studies. Eur Neuropsychopharmacol. 2011; 21(8): 600–620.
- Ghanizadeh A. Systematic review of clinical trials of aripiprazole for treating attention deficit hyperactivity disorder. Neurosciences (Riyadh). 2013; 18(4): 323–329.
- Lamberti M, Siracusano R, Italiano D, et al. Head-to-Head Comparison of Aripiprazole and Risperidone in the Treatment of ADHD Symptoms in Children with Autistic Spectrum Disorder and ADHD: A Pilot, Open-Label, Randomized Controlled Study. Paediatr Drugs. 2016; 18(4): 319–329.
- Filipska K, Pietrzykowski Ł, Ciesielska N, et al. Zaburzenia depresyjne u osób w podeszłym wieku- przegląd literatury. Gerontologia Polska. 2015; 4: 165–169.
- Rado J, Janicak PG. Aripiprazole for late-life schizophrenia. Clin Interv Aging. 2010; 5: 253–258.
- Pigott TA, Carson WH, Saha AR, et al. Aripiprazole Study Group. Aripiprazole for the prevention of relapse in stabilized patients with chronic schizophrenia: a placebo-controlled 26-week study. J Clin Psychiatry. 2003; 64(9): 1048–1056.
- Chrzanowski WK, Marcus RN, Torbeyns A, et al. Effectiveness of long-term aripiprazole therapy in patients with acutely relapsing or chronic, stable schizophrenia: a 52-week, open-label comparison with olanzapine. Psychopharmacology (Berl). 2006; 189(2): 259–266.
- Madhusoodanan S, Brenner R, Gupta S, et al. Clinical experience with aripiprazole treatment in ten elderly patients with schizophrenia or schizoaffective disorder: retrospective case studies. CNS Spectr. 2004; 9(11): 862–867.
- Bharadwaj B, Kattimani S, Mukherjee A. Aripiprazole for acute mania in an elderly person. Ind Psychiatry J. 2011; 20(2): 142–144.
- Wu WY, Chan HY, Tan HKL. Suppression of antipsychotic-induced tardive dyskinesia with aripiprazole in an elderly patient with bipolar I disorder. Acta Neuropsychiatr. 2014; 26(1): 61–64.
- Carton L, Cottencin O, Lapeyre-Mestre M, et al. Off-Label Prescribing of Antipsychotics in Adults, Children and Elderly Individuals: A Systematic Review of Recent Prescription Trends. Curr Pharm Des. 2015; 21(23): 3280–3297.
- Kirino E. Use of aripiprazole for delirium in the elderly: a short review. Psychogeriatrics. 2015; 15(1): 75–84.
